How to Chose A Coral Springs Zantac Attorney
Zantac (known chemically as ranitidine), has been a popular over-the-counter heartburn drug for years. However, in fall 2019, lawsuits were filed in multiple states alleging that Zantac led to the production of an unhealthy amount of N-Nitrososdimethylamine (“NDMA”) when repeatedly digested by the human body, leading to the development of cancer. NDMA is a potent carcinogen—it was a chemical biproduct of the production of rocket fuel in the early 1900s and today, according to one complaint, is used to induce tumors in animals as part of laboratory experiments. The FDA stated that the allowable daily limit of NDMA is 92 nanograms; in a single dose of Zantac researchers are discovering over 3 million nanograms of NDMA.
In September 2019, Novartis and Apotex announced that they were recalling all of their generic ranitidine products sold in the United States and on October 2, 2019, the FDA stated that it was ordering all manufacturers of Zantac and ranitidine products to conduct testing for NDMA and that preliminary results indicted unacceptable levels of NDMA. The Zantac litigation is still in its infancy but as more and more new cases were filed as 2019 drew to a close, a 2020 Zantac MDL seems likely.
In January 2020, a proposed class action suit was filed against Pfizer Inc., in the Southern District of New York, by named plaintiff Dana Viola. The proposed class action alleges that Pfizer, which manufactured and marketed Zantac from 2000 through 2006, advertised the drug as safe and effective despite scientific evidence that pointed to unsafe levels of NDMA, rendering the drug unfit for human consumption.
The suit further alleged that the original Zantac label did not represent NDMA as an ingredient in the medication and did not provide any disclosures as to NDMA’s cancer-causing properties. The complaint further argued that, had the medication been properly synthesized, NDMA would not be present in it. The suit is seeking statutory damages, damages for the injuries sustained in consuming high levels of acutely toxic NDMA and damages related to the defendant’s conduct.
The cases are: Galimidi v. Sanofi US Services Inc., Case No.: 95707176, in the Circuit Court of the 11th Judicial Circuit in and For Miami-Dade County, Florida, Blake v. Boehringer Ingelheim Pharmaceuticals Inc. et al., case number 1:19-cv-02991, in the U.S. District Court for the District of Colorado and Dana Viola et al. v. Pfizer Inc., Case No.: 1:20-cv-00004, in the U.S. District Court for the Southern District of New York.
Coral Springs Zantac Attorney Evan Ostfeld
Let The Law Offices of Evan M. Ostfeld, P.A., and their co-counselling firms provide you with representation to pursue your claims for injuries caused by the use of Zantac. Contact us today for a no obligation case evaluation at (866) 478-3968, (954) 227-7529, (954) 998-0075 text or email at email@example.com to discuss your situation with us. We look forward to the opportunity to help you receive compensation for the use of this product.